Critical Path Institute’s® Translational Therapeutics Accelerator today officially launched its 2026 global Request for Proposals for Bridging Research and Innovation in Drug Development Grants. These ...
TUCSON, Ariz., October 14, 2025 — Critical Path Institute® (C-Path) announced it has been selected to receive the 2025 Innovation Award by Reagan-Udall Foundation for the FDA, part of the Foundation’s ...
Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results